Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2013
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
Details : Undisclosed
Product Name : Myfortic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2010
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2010
Lead Product(s) : Mycophenolate Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable